Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Morepen Laboratories Limited

NSE: MOREPENLABPharmaceuticalsASM stage 1

Share price

₹136.55

-7.09% close of 8 Oct 2026

Market cap ₹7,510 CrP/E 63.6

Business score

How strong the business is, in one number. The parts behind it are in Pro.

52

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹7,510 Cr

P/E ratio

63.6

P/B ratio

6.0

ROCE

8.1%

ROE

5.3%

Dividend yield

0.1%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹146.9752-week low ₹33.68

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Our sales figures for this company step up at Mar 2006 and we hold nothing that says why, so we cannot honestly quote a growth rate across it.

Whether it grew faster than its sector

Our sales figures for this company step up at Mar 2006 and we hold nothing that says why, so there is no honest growth rate of its own to set against its sector.

Room to re-rate, or risk of de-rating

At 63.6× earnings it costs 2.7× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 29.0×, the 100th percentile of its own range.

Whether growth justifies the valuation

Priced at 3.5 times its growth rate, on earnings growth of 18%.

Profit growthPrice per ₹1 profitPer 1% growth
Morepen Laboratories Limited — this one18%/yr63.6×₹3.5
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 93 of 130 on returns, 43 of 127 on growth, 108 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 8.1% on capital, ahead of 28% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years the business itself consumed ₹13 crore of cash before any plant spend, funded from lenders and shareholders. But only about 40 of every 100 rupees of profit it reported over 12 years arrived as cash — the rest is tied up. Its cash comes back more slowly than it used to: it went from being waiting 55 days for its cash to waiting 118 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 9 checks clear · 67%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue and profit came in far above the pre-result Uniresearch forecast.

Announced 4 Aug 2026 · Consolidated · Unaudited

Revenue

₹570 Cr

Revenue vs last year

+34.1%

Revenue vs last quarter

+17.6%

Net profit

₹56 Cr

Profit vs last year

+412.7%

Profit vs last quarter

+252.5%

Net margin

9.9%

EPS

₹1.03

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹7,510 Cr
Prev close
₹136.55
52w High
₹151
52w Low
₹33.0
Enterprise value
₹7,626 Cr
Beta
1.8
Price CAGR 1y
206.0%
Price CAGR 3y
62.0%
Price CAGR 5y
21.0%
Price CAGR 10y
20.0%

Ratios

Return on assets
5.0%
PEG ratio
3.5
P/E ratio
63.6
P/B ratio
6.0
EV / EBITDA
41.4
Industry P/E
38.0
ROCE
8.1%
ROCE 5y average
14.2%
ROE
5.3%
Debt / Equity
0.2
Interest coverage
8.5
Dividend yield
0.1%
ROE 3y average
9.0%
ROE last year
5.0%

Annual P&L

Annual revenue
₹1,806 Cr
Annual profit
₹96 Cr
Operating margin
7.0%
Net profit margin
5.3%
EBITDA margin
7.0%
Sales growth 3y
8.4%
Sales growth 5y
8.7%
Profit growth 3y
18.0%
Profit growth 5y
-8.0%
EPS
₹1.7
Sales growth TTM
9.0%
Profit growth TTM
27.0%
Dividend payout
12.0%

Quarter P&L

Sales latest quarter
₹570 Cr
Profit latest quarter
₹56 Cr
YoY quarterly sales growth
34.1%
YoY quarterly profit growth
409.1%
OPM latest quarter
14.5%

Balance Sheet

Book Value
₹22.7
Face Value
₹2.0
Total debt
₹208 Cr
Total cash
₹69 Cr
Borrowings
₹208 Cr
Reserves / Equity
10.3

Cash Flow

Operating cash flow
₹33 Cr
Free cash flow
-₹127 Cr
FCF yield
-1.9%
Net cash flow
₹4 Cr

Shareholding

Promoter holding
35.7%
FII holding
3.4%
DII holding
1.7%
Public holding
59.2%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,766.9033.54,23,9390.902,901.26.015,299.910.520.5
Divi's Lab.9,510.0084.72,52,4610.31902.065.53,080.027.822.0
Torrent Pharma.4,639.4579.11,76,4700.81566.05.84,921.054.915.2
Zydus Lifesci.1,115.0022.81,11,2220.09990.2-35.18,017.022.021.1
Laurus Labs2,021.1099.91,09,2030.10362.1125.52,026.329.117.8
Cipla1,305.0029.41,05,4270.98785.6-39.27,119.32.315.5
Mankind Pharma2,425.0046.91,00,1630.04574.129.64,030.612.913.5
Morepen Labs.140.2565.57,6850.1456.4424.6570.134.18.1
Median416.7034.22,1300.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales401422445423455438453466425412484485570
Expenses375388394375404394417424401381438460488
Material Cost268238221294291328
Change in Inventories-247.6212-13-8.72-19
Purchases of Stock-in-Trade71173216189.64
Employee Cost575557625962
Other Expenses51836078102106
Operating Profit26345148524436422431462483
OPM %6.517.96111111107.989.075.687.469.575.0414
Other Income23443555430485
Exceptional items (within Other Income)0026000
Interest0021111544445
Depreciation88810625169111068
Profit before tax21294442484635261646352375
Tax %29262732252424212610223324
Net Profit15213229363527201141281656
EPS in Rs0.290.420.630.550.710.640.490.370.200.750.500.291.03
Diluted EPS in Rs0.350.200.750.500.281.03

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales4014855956077698531,1881,5471,4181,6901,8121,8061,951
Expenses3524245345427017851,0701,4101,3381,5321,6381,6801,767
Material Cost9991,043
Change in Inventories-47-2.15
Purchases of Stock-in-Trade20782
Employee Cost209233
Other Expenses269324
Operating Profit48626165686911913780159174126184
OPM %1213101198109691079
Other Income1-344491210614184748
Exceptional items (within Other Income)026
Interest91084222-7248.341617
Depreciation39353434403730282833293636
Profit before tax213243029399912756135155120179
Tax %6-10011412031292420
Net Profit2132430293497102399711896141
EPS in Rs0.050.280.530.660.640.752.162.130.761.882.151.732.57
Diluted EPS in Rs2.201.73
Dividend Payout %0000000000912

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
14%
5 years
9%
3 years
8%
TTM
9%

Compounded profit growth

10 years
14%
5 years
-8%
3 years
18%
TTM
27%

Stock price CAGR

10 years
20%
5 years
21%
3 years
62%
1 year
206%

Return on equity

10 years
12%
5 years
10%
3 years
9%
Last year
5%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital9090909090909096102102110110
Reserves78911061361631943354836517451,0471,137
Borrowings20118716913413213317192529105208
Other Liabilities121156173226230246416473332417517482
Minority Interest310.65
Total Liabilities4895245385866156638581,0701,1101,2931,7781,936
Fixed Assets322297272264236216225252267307489513
CWIP00000021417242822
Investments000001100185124
Other Assets1672272663213794466318048279601,1761,277
Total Assets4895245385866156638581,0701,1101,2931,7781,936

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity51504163171151-60-91733233
Cash from Investing Activity-32-27-14-27-13-12-70-32-47-83-322-126
Cash from Financing Activity-19-27-24-38-054766144530097
Net Cash Flow-0-43-14428-266-5104
Free Cash Flow464131376-610-127-137-8-182-126

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days516657736459565968706567
Inventory Days555165766991829687859488
Days Payable126140125173124113989087101114103
Cash Conversion Cycle-20-23-3-24937406569544553
Working Capital Days-20-10-86-62-34-817559894107118
ROCE %38998102323817158

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Sep 2026
Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters383838363636363636363636
FIIs2.111.851.672.082.221.941.721.621.621.591.463.43
DIIs2.212.152.141.691.641.671.501.491.251.251.281.70
Government0.010.010.010.010.010.010.010.010.010.010.010.01
Public575858616061616161626259
No. of Shareholders3,04,2893,36,0193,48,7664,30,9294,48,3614,68,8604,61,1804,61,8534,53,1374,47,2864,34,9124,03,932

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +185.0% (₹47.91 → ₹136.55)Brick size ₹7.93 (fixed)Bricks 13
₹50.00₹100₹137Jun '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹136.55 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

116inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

87,60,787inr

2026-03-31

News

News and filings about Morepen Laboratories Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Makes products for

  • Unnamed global pharma company

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE083A01026

Plants

  • Morepen Baddi facility
  • Morepen Masulkhana facility
  • Morepen Parwanoo facility

News impact

Big market events that reach Morepen Laboratories Limited, and how the effect spreads.

Who it hits first

  • Morepen Laboratories Limited, a small Indian drug maker, has filed its first drug application in the United States for a copy (generic) of a diabetes pill that works as a DPP-4 inhibitor, which helps control blood sugar.
  • A first US filing opens the door to future US sales if the American drug regulator approves it, but approval takes many months and the article calls it a late entry into a crowded diabetes market.
  • Morepen shares sit under mid-stage exchange watch (ASM stage 1), so any price pop may be capped by trading curbs.

Who may gain

  • Morepen Laboratories itself, the filing company, gains a first shot at the large US diabetes market if approval comes through.
  • No other company gains directly in this pack: the ten listed rivals are large incumbents or ingredient makers, and a single early filing by a small player does not send them business.

Along the supply chain

Downstream

Downstream, no distributor or pharmacy chain is named, and US patients would only benefit much later if a cheaper generic reaches shelves after approval.

Upstream

Upstream, the pack lists no suppliers for Morepen, so no ingredient or equipment maker gains work from this filing.

Where demand moves

Business

Business demand does not move yet: a filing is a request for approval, not an order, so no factory gains sales until the US regulator clears the pill and buyers place orders.

Capital

Investor money may buy a little Morepen on US hopes, while largely ignoring its large rivals, though exchange watch (ASM stage 1) and the long wait for approval temper excitement.

How it spreads across sectors

Healthcare

A small first US filing lifts sentiment for tiny filers but leaves large drug makers untouched, as one early diabetes copy does not change market shares.

When it plays out

Immediate

1-7 days: Morepen may see talk-driven moves under ASM curbs; rivals stay flat as the filing is too early to matter.

Medium term

1-6 months: Filing sits in review with no revenue; real impact only comes if approval and launch milestones arrive later.

Short term

1-4 weeks: Watch for US regulator acceptance of the filing and any Morepen update on timelines; no sales yet.

Who it hits first

  • Zydus Lifesciences, the Ahmedabad-based drug maker, had its New Jersey site's drug-safety monitoring system inspected by the US Food and Drug Administration from September 22 to 25.
  • The inspection closed with nil (zero) observations, meaning the inspectors found no problems needing corrective action.
  • This removes a near-term regulatory worry for Zydus's US business but does not by itself create new sales.

Who may gain

  • Zydus Lifesciences — lower US regulatory risk and steadier sentiment for its existing US drug sales.
  • Zydus shareholders — reduced overhang of a warning letter or import restriction at this New Jersey site.

Along the supply chain

Downstream

US distributors, pharmacies and patients see continued supply confidence, but no price or volume shift — this clearance does not approve a new drug.

Upstream

Ingredient, packaging and service suppliers to Zydus see no direct order change — a clean safety-system inspection keeps existing production running rather than adding new volume.

Where demand moves

Business

No new purchase orders flow from this clearance — it is a compliance pass, not a contract win — but it protects Zydus's existing US drug sales from disruption.

Capital

Investors are likely to give Zydus a small relief premium as US regulatory risk falls, with little fresh money moving into rival drug stocks on this news alone.

How it spreads across sectors

Healthcare

Mild positive sentiment for Indian drug exporters on clean USFDA news, but no sector-wide earnings change since the clearance is specific to one Zydus site.

When it plays out

Immediate

1-7 days: Zydus shares firm modestly on relief; rival drug stocks barely move.

Medium term

1-6 months: no lasting uplift unless followed by new US approvals or launches linked to the site.

Short term

1-4 weeks: focus shifts back to Zydus's US pipeline and pricing; the inspection fades as a price driver.

15 Sept, 18:24 IST · Market event · high impact

Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler

Aurobindo won US approval for its first asthma inhaler, opening new American sales that should lift its shares modestly, while rival inhaler makers face slightly tougher competition and most other drug stocks stay unaffected.

Healthcare

Who it hits first

  • Aurobindo Pharma received its first USFDA approval for a metered-dose asthma inhaler (reported as a generic of QVAR/beclomethasone, to be made at its Raleigh facility in America), taking total US generic approvals to 596 and opening a new hard-to-copy revenue stream.
  • Near-term revenue from one inhaler is small next to Aurobindo's total sales, so the share-price lift should be modest; the bigger prize is proving its inhaler factory and know-how work, which can bring more inhaler approvals over 1-2 years.

Who may gain

  • Aurobindo Pharma: new US inhaler sales plus better use of its American inhaler factory.
  • Laurus Labs (mild): a supplier to Aurobindo that could see a small rise in orders as inhaler volumes grow - but one product alone moves very little.
  • No rival drugmaker gains from this approval; peers selling rival inhalers in America face a little more competition.

Along the supply chain

Downstream

American wholesalers, pharmacies and insurers gain a cheaper generic inhaler option, which can trim their costs slightly; no India-listed company sits downstream of this launch in a way that moves its stock.

Upstream

Aurobindo's suppliers, including Laurus Labs which supplies materials to Aurobindo, get a small positive readthrough as inhaler production ramps up; with a single product launching, extra orders start tiny and only matter if more inhalers follow.

Where demand moves

Business

Doctors and pharmacies can switch some asthma patients from the costlier branded inhaler to Aurobindo's cheaper generic, moving a slice of demand to Aurobindo; no supply is disrupted and no demand is destroyed, so the shift is small and one-directional.

Capital

Some short-term money may buy Aurobindo on the approval news, but one product approval is too small to pull money across the drug sector - no broad rotation expected.

How it spreads across sectors

Healthcare

Mildly positive signal for the drug sector: another Indian maker has cracked complex inhalers, supporting the shift toward harder-to-copy US products - but one more competitor for peers with American inhaler sales (Cipla, Lupin, Glenmark), a small negative for them.

Commodity angle

Cc skip reason

no_commodity_link

When it plays out

Immediate

Aurobindo shares likely rise modestly (2-3%) over 1-7 days as traders price in the approval; watch the launch-date announcement and analyst notes sizing the product's sales.

Medium term

Over 1-6 months, actual US inhaler sales and prescription share decide the real gain; success also de-risks Aurobindo's next inhaler filings, which would matter more than this single approval.

Short term

Over 1-4 weeks, focus shifts to launch timing, initial stocking orders and whether Aurobindo guides on inhaler revenue; approval euphoria usually fades until sales show up.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

18 Sep 2026unspecified₹0.2
29 Aug 2025unspecified₹0.2

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
16 Sep 2026HRTI PRIVATE LIMITEDSELL28,13,508₹107.18
16 Sep 2026HRTI PRIVATE LIMITEDBUY25,28,438₹106.12
31 Aug 2026HRTI PRIVATE LIMITEDSELL31,84,756₹105.94
31 Aug 2026HRTI PRIVATE LIMITEDBUY31,76,302₹105.50
20 Aug 2026HRTI PRIVATE LIMITEDSELL31,04,810₹93.72
20 Aug 2026HRTI PRIVATE LIMITEDBUY30,05,655₹93.44
20 Aug 2026QE SECURITIES LLPSELL29,64,621₹93.39
20 Aug 2026QE SECURITIES LLPBUY29,34,639₹93.91
17 Aug 2026HRTI PRIVATE LIMITEDSELL41,27,672₹87.28
17 Aug 2026HRTI PRIVATE LIMITEDBUY36,72,287₹87.31

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.